Slide 1: BioSyent Inc. Q1 FY2025 Results
BioSyent BioSyentInc. Inc. Q4 Q1 / FY2025 2023Results Results MARCH 13, 2025 2024 MAY 15, PRESENTED BY: RENÉ GOEHRUM PRESENTED BY: RENÉ GOEHRUM PRESIDENT AND CEO PRESIDENT AND CEO 1 | www.biosyent.com | TSXV: RX 1 | www.biosyent.com | TSXV: RX
Slide 2: Disclaimer
DISCLAIMER This presentation is for informational purposes only and should not be considered as an offer to buy or sell securities. No stock exchange has either approved or disapproved of the information that is contained in this presentation. This presentation may contain forward-looking statements
Slide 3: 3 | www.biosyent.com | TSXV: RX | www.biosyent.com | TSXV: RX
3 | www.biosyent.com | TSXV: RX 3 | www.biosyent.com | TSXV: RX
Slide 4: Sales, EBITDA and NIAT
Sales, EBITDA and NIAT Quarter ended March 31st (Q1) +42% Record Quarterly Sales 10,000 +35% 8,000 EBITDA Margin: 29% to Sales CAD (000's) 6,000 NIAT Margin: 21% to Sales 4,000 +45% +31% 2,000 10,979 6,483 1,517 1,175 7,734 2,204 1,769 3,202 2,320 0 Q1 2023 Q1 2024 Q1 2025 Sales EBITDA NIAT 4 | www.
Slide 5: Q1 2025 Sales Summary ($)
Q1 2025 Sales Summary ($) Q1 2025 Sales ($) Q1 ‘25 vs. Q4 ’24 (%) Canadian Pharma ($) $9,160k +21% Cathejell® +15% Combogesic® (30%) FeraMAX® Pd +18% Gelclair® (21%) Inofolic® +401% RepaGyn® +9% Tibella® (Canada) +53% International Pharma ($) $1,535k n/a Legacy ($) $284k +52% Total Company ($) $10,9
Slide 6: Fully Diluted Earnings per Share (TTM)
Fully Diluted Earnings per Share (TTM) 0.7 59 Consecutive $0.67 0.6 Profitable Quarters to Q1 2025 0.5 $0.59 0.4 $0.41 0.3 $0.20 0.2 $0.20 $0.20 $0.15 $0.12 $0.10 $0.14 $0.12 0.1 $0.12 $0.13 $0.10 $0.09 0 Q2 2022 Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025
Slide 7: 2025 YTD Highlights
2025 YTD Highlights Jan/Feb 2025: First Tibelia® Global shipments made by BioSyent: ~$0.8 million in incremental revenue Orders booked for shipping Q2, Q3, Q4 Mar 2025: Paid Q1 2025 dividend of $0.05/share (+11% increase vs. 2024) May 2025: Q2 2025 Dividend of $0.05/share declared Apr 2025
Slide 8: Trade and Tariffs
Trade and Tariffs Uncertainty: USA-Canada Tariffs / Counter-Tariffs Impact on Global Trade and Economies Impact on Supply Chains Impact on Canadian Consumers 8 | www.biosyent.com | TSXV: RX
Slide 9: Most recommended iron supplement in Canada
Most recommended iron supplement in Canada - pharmacists and physicians - 10 consecutive years(1) Continued innovation and expansion of FeraMAX® product line for iron health (1) Based on Pharmacy Practice + Business, The Medical Post and Profession Santé 2025 Survey on OTC Counselling and Recomm
Slide 10: FeraMAX® LifeCycle Strategy
FeraMAX® LifeCycle Strategy Expanding leadership of FeraMAX® brand in Canada: “Iron health for life” FeraMAX® Pd platform introduced in October 2020 Patented delivery system based on Polydextrose Iron Complex (PDIC) FeraMAX® Pd Therapeutic 150 launched Nov 2020 FeraMAX® Pd Powder 15 launch
Slide 11: Innovations, Product Launches and Acquisitions
Innovations, Product Launches and Acquisitions Tibella® Jul 2020 FeraMAX® Pd Oct 2020 FeraMAX® Pd Therapeutic 150 Nov 2020 Combogesic® Dec 2020 FeraMAX® Pd Powder 15 Oct 2021 FeraMAX® Pd Maintenance 45 Mar 2023 Inofolic® Aug 2023 Gelclair® Nov 2023 Tibelia® Global Sep 2024 New endocrinology asset TB
Slide 12: 15 Years of Profitable Growth (and Counting!)
15 Years of Profitable Growth (and Counting!) Tibelia Global Total Company Annual Revenue 40,000 35,000 30,000 25,000 CAD 000'S 20,000 15,000 10,000 5,000 0 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 *2025* f/d shares: 14,336,194 11,579,121 12 | www.biosyent.com | TSX
Slide 13: Cash Balance & Return on Equity (“RoE”)
Cash Balance & Return on Equity (“RoE”) Trailing Twelve Months ended March 31st 30,000 25% • Zero Debt 27,794 21% 22% 25,000 26,249 • TTM Cash from Operations of 20% 24,899 $7.0M 15% 20,000 • TTM NCIB share buybacks: 15% $4.1 M CAD (000's) RoE % 15,000 • TTM Dividends of $2.1M 10% 10,000 • Mar 31/25
Slide 14: Capital Allocation linked to Strategy
Capital Allocation linked to Strategy First use of capital is to generate revenue/profit growth & portfolio diversification. Capital Light, Cash-Generating Quarterly Dividends Business Model $5.6 M to Date Q4’22 – Q2’25 Share Buybacks $22.6 M to Date 3.1 million shares repurchased since 2018 •7 new
Slide 15: Stock Information
Stock Information As at May 13, 2025 Exchange & Trading Symbol 0% TSXV: RX May 13, 2025 Closing Stock Price (CAD) (TSXV): $10.80 52 Week Hi/Low (TSXV): $12.13 / $8.24 Issued Common Shares: 11,471,121 Treasury – RSU Shares in Trust (216,483) Outstanding Common Shares: 11,254,638 Options Outstanding 1
Slide 16: Profitable. Well Capitalized. Growth Assets.
PROFITABLE. WELL CAPITALIZED. GROWTH ASSETS. FOCUSED ON LONG-TERM GROWTH AND TOTAL SHAREHOLDER RETURN. 16 www.biosyent.com | TSXV: RX